Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 398,700 shares, a decrease of 17.2% from the January 31st total of 481,400 shares. Based on an average trading volume of 669,500 shares, the short-interest ratio is currently 0.6 days.
Institutional Investors Weigh In On Milestone Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp increased its stake in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after acquiring an additional 10,000 shares during the last quarter. National Bank of Canada FI increased its stake in Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after acquiring an additional 11,600 shares during the last quarter. PVG Asset Management Corp bought a new position in Milestone Pharmaceuticals in the third quarter valued at $46,000. Atria Investments Inc increased its stake in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company's stock valued at $61,000 after acquiring an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Milestone Pharmaceuticals in the fourth quarter valued at $73,000. Hedge funds and other institutional investors own 86.18% of the company's stock.
Milestone Pharmaceuticals Price Performance
Shares of MIST stock traded down $0.06 on Friday, reaching $1.84. The company's stock had a trading volume of 1,012,767 shares, compared to its average volume of 354,718. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The company has a market capitalization of $98.12 million, a P/E ratio of -2.27 and a beta of 1.83. The stock's 50 day simple moving average is $2.05 and its 200-day simple moving average is $1.78.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Friday, February 28th.
View Our Latest Report on MIST
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Featured Articles
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
